STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to ...
I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted ...
STERIS' STE strong rebound of procedure volumes in the United States is leading to solid growth in the Healthcare business. The company carries a Zacks Rank #2 (Buy) at present. STERIS’ Healthcare ...
Steris reported strong growth in their Healthcare Products and Life Sciences segments, driven by procedure volume increases and market share gains. The company has raised their full-year organic ...
Narrow-moat Steris had a good fiscal third quarter, moderately exceeding both our expectations and consensus aggregated by FactSet. While operating costs were a bit higher than anticipated--due to ...
STERIS plc, a leading provider of infection prevention and procedural products and services, has demonstrated resilience in the face of economic challenges while maintaining a strong market position.
STERIS stock (NYSE: STE), a healthcare company focused on infection prevention, has seen a 29% fall this year, slightly underperforming the broader S&P500 index, down 21%. However, in the longer term, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback